Pitavastatin Unique and Effectual for Treating Primary and Mixed Hyperlipidemia

Pitavastatin Unique and Effectual for Treating Primary and Mixed Hyperlipidemia

PitavastatinPitavastatin is often recognized by it’s brand name LOVALO, which is marketed by Kowa/Lilly. With the patent for LOVALO due to expire on May 19, 2015, this remarkable statin stands to create quite a stir as a generic product. Approved to treat both primary hyperlipidemia and mixed dyslipidemia, pitavastatin is unique as it offers an uncommon cyclopropyl group on the base structure. This distinctive component of pitavastatin creates an extremely effective inhibition of the HMG-CoA reductase enzyme, thus inhibiting the production of cholesterol. In addition, this inhibition renders a greater amount of low-density lipoprotein cholesterol clearance, as well as a substantial reduction of plasma cholesterol.

Offered in tablet dosing ranging from 1, 2 and 4 milligram strengths, the usual starting dose is 2 milligrams daily. Pitavastatin is especially efficacious when combined with both a diet and exercise program. Minimal side effects have been reported, and include constipation, diarrhea, myalgia and pain in extremities. There have been many clinical trials touting the effectual nature of pitavastatin. One particular study involved 942 elderly patients over the age of 62. This study was randomized, double- blind and multi-center, and consisted of patients with both primary and mixed dyslipidemia. After a six to eight week lead in to the study, consisting of a “dietary washout”, patients then received a once daily dose of either pitavastatin (Livalo) or pravastatin. The study lasted for twelve weeks, and compared 1 milligram of pitavastatin with 10 milligrams of pravastatin, 2 milligrams of pitavastatin versus 20 milligrams of pravastatin, and 4 milligrams of pitavastatin opposite 40 milligrams of pravastatin. Results supported the use of pitavastatin over pravastatin in terms of it’s effectiveness in the lowering of participants low-density lipoprotein cholesterol amounts by an average of 9 percent. With the CDC reporting that one in every six adults, or 16.3 percent of the U.S. population of adults has high total cholesterol, this number is sure to rise as the life expectancy for Americans rises.

LGM Pharma is a supplier of the API Pitavastatin CAS# 147511-69, for research and development purposes.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service